Elicio Therapeutics Inc. (NASDAQ:ELTX) — Market Cap & Net Worth
Market Cap & Net Worth: Elicio Therapeutics Inc. (ELTX)
Elicio Therapeutics Inc. (NASDAQ:ELTX) has a market capitalization of $189.30 Million ($189.30 Million) as of May 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16748 globally and #3787 in its home market, demonstrating a -9.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Elicio Therapeutics Inc.'s stock price $10.75 by its total outstanding shares 18396074 (18.40 Million). Analyse how efficiently does Elicio Therapeutics Inc. generate cash to see how efficiently the company converts income to cash.
Elicio Therapeutics Inc. Market Cap History: 2021 to 2026
Elicio Therapeutics Inc.'s market capitalization history from 2021 to 2026. Data shows change from $533.49 Million to $197.76 Million (-41.00% CAGR).
Index Memberships
Elicio Therapeutics Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #461 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1648 of 3165 |
Weight: Elicio Therapeutics Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Elicio Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Elicio Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
18.84x
Elicio Therapeutics Inc.'s market cap is 18.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $533.49 Million | $28.31 Million | -$26.40 Million | 18.84x | N/A |
Competitor Companies of ELTX by Market Capitalization
Companies near Elicio Therapeutics Inc. in the global market cap rankings as of May 5, 2026.
Key companies related to Elicio Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Elicio Therapeutics Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, Elicio Therapeutics Inc.'s market cap moved from $533.49 Million to $ 197.76 Million, with a yearly change of -41.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $197.76 Million | +35.05% |
| 2025 | $146.43 Million | +56.08% |
| 2024 | $93.82 Million | -38.85% |
| 2023 | $153.42 Million | +2.71% |
| 2022 | $149.38 Million | -72.00% |
| 2021 | $533.49 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Elicio Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $189.30 Million USD |
| MoneyControl | $189.30 Million USD |
| MarketWatch | $189.30 Million USD |
| marketcap.company | $189.30 Million USD |
| Reuters | $189.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targ… Read more